Popular terms

Rheumatoid Arthritis topics
Rheumatoid Arthritis
Osteoarthritis
Autoimmune
Multiple Sclerosis
Immune Disease
Autoimmune Disease
Antibodies
Astaxanthin
Hyaluronate
Hyaluronic Acid
Joint Pain
Hyaluronan
Immune Diseases
Autoimmune Diseases
Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Rheumatoid Arthritis patents

      

This page is updated frequently with new Rheumatoid Arthritis-related patent applications.




Date/App# patent app List of recent Rheumatoid Arthritis-related patents
08/11/16
20160229917 
 Antagonist anti-il-7 receptor antibodies and methods patent thumbnailAntagonist anti-il-7 receptor antibodies and methods
The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (il-7r). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids.
Rinat Neuroscience Corp.


08/11/16
20160228505 
 Use of gelsolin to diagnose and treat inflammatory diseases patent thumbnailUse of gelsolin to diagnose and treat inflammatory diseases
The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis).. .
The Brigham And Women's Hospital, Inc.


08/04/16
20160222436 
 Causative agents and diagnostic methods relating to rheumatoid arthritis patent thumbnailCausative agents and diagnostic methods relating to rheumatoid arthritis
Methods, reagents and compositions thereof for predicting ra onset in susceptible individuals, diagnosing ra onset, and/or evaluating efficacy of a therapeutic regimen for treating ra are described herein. Determining the amount of a particular bacterial species comprising seq id no: 1, seq id no: 2, or seq id no: 3 (seq id no: 1+bacteria) serves as a biomarker for the above indications..

08/04/16
20160220582 
 Combination of lupeol acetate and curcumin used for the treatment or prevention of activated osteoclast precursor associated disorders patent thumbnailCombination of lupeol acetate and curcumin used for the treatment or prevention of activated osteoclast precursor associated disorders
The present invention relates to synergistic combinations of lupeol acetate and curcumin at low dosage, and their use for the treatment or prevention of activated osteoclast precursor related diseases, including rheumatoid arthritis and osteoporosis.. .
National Yang-ming University


07/28/16
20160215044 
 High concentration formulations of anti-c5 antibodies patent thumbnailHigh concentration formulations of anti-c5 antibodies
The present disclosure relates to, inter alia, stable aqueous solutions comprising a high concentration of an antibody that binds to human complement component c5 and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders (for example, age-related macular degeneration or rheumatoid arthritis) using the solutions.
Alexion Pharmaceuticals, Inc.


07/28/16
20160213676 
 Substituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis patent thumbnailSubstituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the retinoic acid-related orphan nuclear receptor γt (rorγt)/rorγ. The compounds of the present invention are useful for modulating rorγt)/rorγ activity and for treating diseases or conditions mediated by rorγt)/rorγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as multiple sclerosis (ms), rheumatoid arthritis (ra), inflammatory colitis, psoriasis, copd, pain, obesity, diabetes, dyslipidemia, osteoporosis, asthma, neurodegenerative diseases and cancer..
Arrien Pharmaceuticals Llc


07/28/16
20160213627 
 Substituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis patent thumbnailSubstituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the retinoic acid-related orphan nuclear receptor γt (rorγt)/rorγ. The compounds of the present invention are useful for modulating rorγt)/rorγ activity and for treating diseases or conditions mediated by rorγt)/rorγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as multiple sclerosis (ms), rheumatoid arthritis (ra), inflammatory colitis, psoriasis, copd, pain, obesity, diabetes, dyslipidemia, osteoporosis, asthma, neurodegenerative diseases and cancer..
Arrien Pharmaceuticals Llc


07/28/16
20160213625 
 Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases patent thumbnailInduced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, huntington's disease, epilepsy, multiple sclerosis (ms), lupus, type-1 and type-2 diabetes, maturity onset diabetes of the young (mody), myasthenia gravis (mg), rheumatoid arthritis (ra), graves' disease, guillain-barré syndrome (gb s), metabolic syndrome, muscular dystrophy or duchenne muscular dystrophy (dmd), severe burns, aging, amyotrophic lateral sclerosis (als), friedreich's ataxia, batten disease, alzheimer's disease, optic neuritis, leber's hereditary optic neuropathy (lhon), autism, rett syndrome, batten disease, angelman's syndrome, leigh disease, fragile-x syndrome, depression, parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous bdnf expression with dnp treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle wasting. Dnp was administered to mice daily over a range of doses, and subsequently bdnf expression in the brain showed a dose dependent and non-linear increase in expression..
Mitochon Pharmaceuticals Llc


07/21/16
20160207997 
 Anti-c5a antibodies patent thumbnailAnti-c5a antibodies
The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to c5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospholipid syndrome, asthma, lupus nephritis, goodpasture's syndrome, and chronic obstructive pulmonary disease.. .
Alexion Pharmaceuticals, Inc.


07/21/16
20160206578 
 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use patent thumbnailAryl-phenyl-sulfonamido-cycloalkyl compounds and their use
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “apsac compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (copd), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc..
Pimco 2664 Limited


07/14/16
20160201130 

Macrophage migration inhibitory factor (mif) promoter polymorphism in inflammatory disease


Describe herein is a novel catt-tetranucleotide repeat polymorphism at position −817 of the human mif gene that functionally affects the activity of the macrophage inhibitory factor (mif) promoter in gene reporter assays. Four genotypes are described which comprise 5, 6, 7, or 8-catt repeat units.
Baxalta Gmbh


07/14/16
20160201056 

Micro-rna regulation of bone loss


The use of mir-34a and agonists thereof in the treatment of bone loss diseases is described. Such conditions include osteoporosis, rheumatoid arthritis and other bone wasting diseases..
The Board Of Regents Of The University Of Texas System


07/14/16
20160200789 

Il4 conjugated to antibodies against extracellular matrix components


A conjugate comprising interleukin-4 (il4) and a specific binding member is disclosed. The specific binding member preferably binds an extra-cellular matrix component associated with neoplastic growth and/or angiogenesis, and the conjugate may be used for targeting il4 to tissues in vivo.
Philogen S.p.a.


07/14/16
20160199338 

Compositions containing monoacetyldiacylglycerol compound as an active ingredient for preventing or treating rheumatoid arthritis


The invention relates to pharmaceutical compositions, as well as health functional food compositions and quasi-drug compositions, for preventing, treating, or improving rheumatoid arthritis, comprising a monoacetyldiacylglycerol compound as an active ingredient. The monoacetyldiacylglycerol of the invention is effective in inhibiting the phosphorylation of stat-3 known to be a therapeutic target for rheumatoid arthritis.
Korea Research Institute Of Bioscience And Biotechnology


07/07/16
20160194336 

P38 mapk inhibitors for the treatment of inflammatory diseases


The present invention provides new p38 mitogen activated protein (map) kinase allosteric inhibitors which are useful for the treatment of p38 mediated diseases such as inflammatory diseases, e.g. rheumatoid arthritis, osteoarthritis, psoriatic arthritis, pain, musculoskeletal system inflammation and musculoskeletal system aging.
Allinky Biopharma


07/07/16
20160193343 

Composition for use in treating and preventing inflammation related disorder


The present invention is related to a use for treating and preventing inflammation related disorder of a composition containing a drug and hyaluronic acid (ha) or ha mixture, whereas the ha or the ha mixture as a delivery vehicle can be a formulation including at least two has having different average molecular weights. The composition has been demonstrated to be capable of reducing the therapeutic dose of a drug on the treatment and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary disease, coeliac disease, conjunctivitis, otitis, allergic rhinitis, gingivitis, aphthous ulcer, bronchitis, gastroesophageal reflux disease (gerd), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (ibd), crohn's disease, irritable bowel syndrome (ibs), intestinal inflammation or allergy, urethritis, cystitis, vaginitis, proctitis, eosinophilic gastroenteritis, or rheumatoid arthritis..
Aihol Corporation


07/07/16
20160193215 

Novel compounds as hif-1 alpha inhibitors and manufacturing process thereof


The present invention relates to novel compounds as hif-1α inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against hif-1α, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer.
Korea Research Institute Of Bioscience And Biotechnology


06/30/16
20160185851 

Antibodies to interleukin-6 and use thereof


The present disclosure provides antibodies that bind to human interleukin-6 (il6). The antibodies can modulate il6 signaling and thus used in treatment or prevention of il6 associated diseases or disorders, particularly inflammatory disorder, rheumatoid arthritis (ra), angiogenesis, and cancer..

06/23/16
20160175310 

Boosting the effect of methotrexate through the combined use with lipophilic statins


The invention relates to the use of an inhibitor of the dihydrofolate reductase enzyme selected from the group that consists of methotrexate, trimetrexate and pemetrexed; or a pharmaceutically acceptable salt thereof, for the preparation of a drug for the treatment or prevention of recurrences of a disease selected from the group that consists of cancer, psoriasis, psoriatic arthritis, juvenile polyarticular arthritis, rheumatoid arthritis, crohn's disease, polymyositis, dermatomyositis and sarcoidosis, wherein said treatment or prevention includes administering to a patient, simultaneously, separately or sequentially, a lipophilic statin and the inhibitor of the dihydrofolate reductase enzyme. The invention also relates to a pharmaceutical composition which includes the inhibitor of the dihydrofolate reductase enzyme and the lipophilic statin together with pharmaceutically acceptable carriers and/or vehicles..

06/16/16
20160168099 

Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use


The present invention relates to novel bisaminoquinoline compounds, pharmaceutical compositions comprising these novel compounds and methods for inhibiting autophagy in biological systems. Methods of treating cancer in patients in need using compounds and/or compositions according to the present invention alone or in combination with at least one additional anticancer agent represent additional aspects of the invention.
The Trustees Of The University Of Pennsylvania


06/16/16
20160166611 

Method of preparing injection solution


A method of preparing an injection solution includes: (1) storing a mixture of a blood sample and a divalent cation chelating agent at a temperature between 2 and 12 degrees celsius for a period of from 3 hours to 72 hours so as to have the mixture with two or more separate layers, wherein a liquid in one of the separate layers contains small somatic stem cells such as sb cells; (2) collecting the liquid from the mixture; and (3) after collecting the liquid from the mixture, mixing the liquid with a solution free from ca2+ into the injection solution. The injection solution can be used for an autoimmune disease, such as ankylosing spondylitis, rheumatoid arthritis, or grover's disease..
Stembios Technologies, Inc.


06/16/16
20160166576 

Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)


This invention relates to amidopyrazole compounds that are inhibitors of interieukin receptor-associated kinases, in particular irak-4, and are useful in the treatment of cellular proliferative diseases. Speifically (5-methylpyridin-2-yl)-1 h-pyrazol-5-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives are disclosed for use in the method of treating inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease and cancer..
Merck Sharp & Dohme Corp.


06/16/16
20160166528 

Compositions containing monoacetyldiacylglycerol compound as an active ingredient for preventing or treating rheumatoid arthritis


The invention relates to pharmaceutical compositions, as well as health functional food compositions and quasi-drug compositions, for preventing, treating, or improving rheumatoid arthritis, comprising a monoacetyldiacylglycerol compound as an active ingredient. The monoacetyldiacylglycerol of the invention is effective in inhibiting the phosphorylation of stat-3 known to be a therapeutic target for rheumatoid arthritis.
Enzychem Lifesciences Corporation


06/09/16
20160160279 

Prognosis of response to treatment with anti-tnf-alpha in patients with rheumatoid arthritis


The invention relates to the use of snp rs3794271, and/or an snp that is in total linkage disequilibrium with same, as a marker in predicting the response to treatment with anti-tnf in a patient with ra. The invention also relates to methods for predicting the response to treatment with anti-tnf, as well as for deciding on or recommending a treatment for a patient with ra, based on determining the genotype for rs3794271 and/or an snp that is in total linkage disequilibrium with same..
Fundacio Hospital Universitari Vall D'hebron- Institut De Recerca


06/09/16
20160159922 

Novel antibodies for the diagnosis and treatment of rheumatoid arthritis


Novel antibodies or binding fragments thereof, which exhibit specific binding to citrullinated epitopes are disclosed, as well as pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in diagnosis, in prognostics, treatment and/or alleviation of rheumatoid arthritis, as well as processes for generating and preparing said antibodies.. .
Vilara Ab


06/09/16
20160159892 

Anti-c5a antibodies


The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to c5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, goodpasture's syndrome, and chronic obstructive pulmonary disease.. .
Alexion Pharmaceuticals, Inc.


06/09/16
20160158330 

Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis


Whereas said treatment being of the individual itself or of ex vivo treatment of isolated dc and or with further labeling with drug, dye or radioisotope and administration back into the patient of the activated and possibly modified dcs for detection, identification, localization and treatment thereof.. .

06/02/16
20160153983 

Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis


The present invention relates to peptides biomarkers that are specifically recognized by autoantibodies present in the sera of patients with rheumatoid arthritis (ra). More specifically, the invention provides epitopes of pad4, of braf, and of calpastatin as well as methods and kits for using these sequences for the diagnosis of ra, in particular for the diagnosis of ra in ccp-negative subjects..
Universite De La Mediterranee - Aix-marseille 11


06/02/16
20160152698 

Anti-ngf antibodies and methods using same


The invention concerns anti-ngf antibodies (such as anti-ngf antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain..
Rinat Neuroscience Corp.


06/02/16
20160151363 

Cadherin-11 inhibitors and methods of use thereof


Cadherin-11 inhibitors and methods for the prevention and treatment of cadherin-11 related diseases are described herein. Cadherin-11 related diseases include cancer and rheumatoid arthritis..
Georgetown University


06/02/16
20160151343 

Non-flushing niacin analogues, and methods of use thereof


One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
Trustees Of Tufts College


05/26/16
20160146831 

Antibody and cytokine biomarker profiling for determination of patient responsiveness


Compositions and methods are provided for prognostic classification of autoimmune disease patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of circulating blood levels of serum autoantibodies and/or cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness.
The Board Of Trustees Of The Leland Stanford Junior University


05/26/16
20160145206 

N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4- hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use


The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted n-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as hmc compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and/or joint destruction and/or bone loss; disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (copd); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumour cancer, such as bladder cancer, breast cancer (female and/or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, such as systemic sclerosis or scleroderma; or a rare vasculitide, such as behçet's disease.
Pimco 2664 Limited


05/19/16
20160136149 

Heteroaryl linked quinolinyl modulators of roryt


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..

05/19/16
20160135782 

Finger joint ultrasound imaging


A method of acquiring ultrasound images for a rheumatoid arthritis examination comprises receiving a hand in a scanning assembly including a transducer array and a fluid providing an acoustic coupling between the transducer array and the hand and identifying locations of a plurality of finger joints of the hand while the hand is held stationary in the scanning assembly. Ultrasound images of the plurality of finger joints are acquired with the transducer array while the hand is held stationary in the scanning assembly, wherein the ultrasound images are of an area less than an entire area of the hand based on the identified locations of the finger joints of the hand..
General Electric Company


05/12/16
20160130340 

Dosing regimens using anti-il-6 antibodies for the treatment of rheumatoid and psoriatic arthritis


The present invention relates to therapeutic methods of using an antibody, or antigen-binding fragment thereof, which selectively binds il-6 for the treatment or prevention of psoriatic arthritis or rheumatoid arthritis and for managing the side effects and symptoms of psoriatic or rheumatoid arthritis and therapeutic compositions for use therein comprising an antibody, or antigen-binding fragment thereof, which selectively binds il-6 for the treatment or prevention of psoriatic or rheumatoid arthritis. The invention further relates to low dosing therapeutic regimens for treating inflammatory il-6 associated diseases, i.e., characterized by elevated 11-6 levels such as psoriatic arthritis or rheumatoid arthritis that provided for reduced adverse side effects and improved safety.
Alderbio Holdings Llc


05/12/16
20160130333 

Chimeric and humanized anti-histone antibodies


The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.


05/12/16
20160130323 

Novel peptides that bind to types of mhc class ii and their use on diagnosis and treatment


It is provided novel peptides from human alpha-enolase, collagen type ii and vimentin that bind to types of mhc class ii that is associated with rheumatoid arthritis. There is also provided novel therapies and methods for diagnosis of rheumatoid arthritis..
Kommstart 872 Ab, 559030-3482


05/12/16
20160130249 

Quinazoline derivatives as vegf inhibitors


The invention relates to quinazoline derivatives of formula (i), wherein m is an integer from 1 to 3; r1 represents halogeno or c1-3alkyl; x1 represents —o—; r2 is selected from one of the following three groups: 1) c1-5alkylr3 (wherein r3 is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, c1-4alkyl, c1-4hydroxyalkyl and c1-4alkoxy; 2) c2-5alkenylr3 (wherein r3 is as defined hereinbefore); 3) c2-5alkynylr3 (wherein r3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (i) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (i) and the pharmaceutically acceptable salts thereof inhibit the effects of vegf, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis..
Astrazeneca Ab


05/05/16
20160123992 

Methods for predicting rheumatoid arthritis treatment response


The invention relates to methods and means for predicting rheumatoid arthritis treatment response.. .
Centre Hospitalier Universitaire De Rouen


05/05/16
20160122768 

Autoimmune disease treatments


There are provided, inter alia, methods and compositions to treat autoimmune disease including invasiveness of fibroblast-like synoviocytes in rheumatoid arthritis.. .
La Jolla Institute For Allergy And Immunology


05/05/16
20160122429 

Anti-tnf- / anti-il-23 bispecific antibodies


Bispecific antibodies are provided that bind tumor necrosis factor alpha (tnfα) and the p19 subunit of interleukin-23 (il-23p19) and are characterized as having high affinity and strong simultaneous neutralizing properties to both tnfα and il-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including inflammatory bowel disease, such as crohn's disease and ulcerative colitis, axial spondyloarthropathy, rheumatoid arthritis and psoriatic arthritis..
Eli Lilly And Company


05/05/16
20160122360 

Tetrahydro-2h-pyrano[3,2-c]isochromene-6-ones and analogs for the treatment of inflammatory disorders


The present invention relates to 2,3,4,4a-tetrahydro-3,4,8,10-tetrahydroxy-2-(hydroxymethyl)-9-methoxypyrano[3,2-c]isochromen-6(10bh)-one analogs of the formula i, wherein, r, r′ and r″ are as herein described. In addition, the invention relates to methods of using compounds for treating or preventing various inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma and chronic obstructive pulmonary disorder..
Council Of Scientific & Industrial Research


05/05/16
20160122336 

Trifluoromethyl alcohols as modulators of roryt


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..

05/05/16
20160122335 

Amide substituted thiazoles as modulators of roryt


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..

05/05/16
20160122334 

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..

05/05/16
20160120995 

Conjugates of polyunsaturated fatty acids and amine-containing compounds and uses thereof


Novel chemical conjugates derived from unsaturated fatty acids and therapeutically active agents, are disclosed. The chemical conjugates are designed and characterized as cox-2 and/or 5-lox inhibitors and are useful in the treatment of inflammatory diseases, dermatitis and disorders such as alzheimer's disease, parkinson's disease, asthma, osteoarthritis, rheumatoid arthritis, pain, primary dysmenorrhea, crohn's disease and ulcerative colitis..
Medwell Laboratories Ltd.


05/05/16
20160120910 

Cell populations having immunoregulatory activity, methods for the preparation and uses thereof


The present invention provides a method for treating rheumatoid arthritis comprising the use of mesenchymal stem cells.. .
Tigenix S.a.u.


05/05/16
20160120850 

Thiazoles as modulators of roryt


The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..

05/05/16
20160120839 

Compositions and methods for the treatment of inflammatory bowel disease


The invention relates to the compounds of formula i and formula ii or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i or formula ii; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
Cellix Bio Private Limited


05/05/16
20160120838 

Compositions and methods for the treatment of inflammatory bowel disease


The invention relates to the compounds of formula i and formula ii or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i or formula ii; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

04/28/16
20160114062 

Treatment of immune, inflammatory and degenerative arthritides with tin-117m


Immune, inflammatory and degenerative arthritides, including rheumatoid arthritis, hemophiliac arthropathy and osteoarthritis, can be treated using a systemic or intra-articular radiosynovectomy technique in which the radionuclide is high specific activity tin-117m. Tin-117m can either be bound to a colloid typically used in an intra-articular radiosynovectomy (rsv), or can be tin-117m annexin for rsv and systemic administration..
Rheumco Llc


04/21/16
20160109442 

Novel test rheumatoid arthritis and kit for rheumatoid arthritis test


Provided are: a novel test method for rheumatoid arthritis; and a kit for rheumatoid arthritis test, which is used in the novel test method for rheumatoid arthritis. A test method for rheumatoid arthritis according to the present invention is characterized by comprising a step for measuring the amount of talin in the plasma or serum of an animal subject.

04/21/16
20160106905 

Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders


This invention uses “targeted apheresis” to treat patients with rheumatoid arthritis and other autoimmune and inflammatory disorders. “targeted apheresis” is a process whereby only the pathogenic and pro-inflammatory elements associated with the disease symptoms are simultaneously and selectively removed from the blood by passing the blood through an extracorporeal affinity device containing selective binding agents.

04/14/16
20160102098 

Bisulfate of janus kinase (jak) inhibitor and preparation method therefor


The present invention relates to a bisulfate of a janus kinase (jak) inhibitor and a preparation method therefor. More specifically, the present invention relates to a (3ar,5s,6as)-n-(3-methoxyl-1,2,4-thiadiazole-5-group)-5-(methyl(7h-pyrrolo[2,3-d]pyrimidine-4-group)amino)hexahydrocyclopenta[c]pyrrole-2(1h)-formamide bisulfate shown in the formula (i), a preparation method therefor, and an application thereof.

04/07/16
20160096899 

Methods for treating juvenile arthritis with anti-bile salt-stimulated lipase (bssl) antibodies


It provides methods and pharmaceutical compositions comprising antagonists to the protein bile salt-stimulated lipase (bssl) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising bssl antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis.
Lipum Ab


04/07/16
20160096895 

Binding members-513


This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (il-1r1). For example, isolated binding members specific for il-1r1 which competes with il-1 and il-1ra for binding to il-1r1 and binds il-1r1 with a kd of 10 pm or less when measured by kinexa™.
Medimmune Limited


03/31/16
20160091490 

Compositions and methods for the diagnosis of rheumatoid arthritis


The present disclosure relates to the field of molecular biology and more specifically to methods for detecting anti-carbamylated protein (anti-carp) antibodies in the serum of rheumatoid arthritis (ra) patients.. .
Leiden University Medical Center


03/24/16
20160083415 

Crystalline anhydrate forms of a pharmaceutical


The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include form i anhydrate and form iv and form v solvates.
Harbor Therapeutics, Inc.


03/24/16
20160083354 

Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same


The present invention relates to novel urea derivatives and, more particularly, to novel urea derivatives with histone deacetylase (hdac) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, their use for the preparation of a medicaments comprising the same, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing novel urea derivatives. The novel urea derivatives as selective histone deacetylase (hdac) inhibitors are effective for the treatment of histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, neurodegeneration, etc..
Chong Kun Dang Pharmaceutical Corp.


03/24/16
20160082017 

Estriol therapy for multiple sclerosis and other autoimmune diseases


The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (ms), rheumatoid arthritis (ra), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis..

03/24/16
20160081578 

Biomarkers for the diagnosis and prognosis of back pain and related conditions


The present invention teaches novel methods of diagnosing and prognosing conditions associated with tissue degeneration and/or pain, including intervertebral disc degeneration, discogenic pain, osteoarthritis, rheumatoid arthritis, and articular cartilage injury. Using the inventive noninvasive imaging methods, the diagnosis and prognosis of back pain and related conditions can be quickly and accurately determined by detecting one or more biomarkers disclosed herein..
Cedars-sinai Medical Center


03/10/16
20160068552 

Vinblastine derivatives, preparation method therefor and application thereof


The present invention provides a new kind of vinca alkaloid derivatives, new applications thereof and preparation methods therefor. The vinca alkaloid derivatives comprise hydrazinolyzed vinca alkaloids and vinca alkaloid dipeptide derivative.
Jinan University


03/10/16
20160068539 

Protease inhibitors


Or a pharmaceutically acceptable salt, n-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin k, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.. .

03/03/16
20160058892 

Preparation of bone-seeking superparamagnetic iron nanoparticles as contrast agents and methods for using the same


Described herein are compositions having a nanoparticle that is conjugated to at least one bone targeting moiety, wherein the bone targeting moiety is bonded to the nanoparticle by a linker, wherein the nanoparticle contains iron, and wherein the compositions are neutral or pharmaceutically acceptable salts or esters. Also described herein are methods of making these compositions.
The Governors Of The University Of Alberta


02/25/16
20160053007 

Antibodies that bind to tl1a and methods of treating inflammatory or autoimmune disease comprising administering such antibodies


Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between dr3 and tl1a. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a t cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease..
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services


02/25/16
20160053004 

Nucleic acides encoding anti-c5a antibodies


The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to c5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, goodpasture's syndrome, and chronic obstructive pulmonary disease.. .
Alexion Pharmaceuticals, Inc.


02/25/16
20160051570 

Treatment of rheumatoid arthritis


A composition for treating chronic inflammation, including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and vitamin d in synergistically effective amounts. A method of treating chronic inflammation, by administering a synergistically effective amount of a composition including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and vitamin d to an individual suffering from chronic inflammation, and treating chronic inflammation.
Ganderland And Associates, Inc.


02/18/16
20160046719 

Antibodies that bind colony stimulating factor 1 receptor (csf1r)


Antibodies that bind csf1r are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind csf1r are also provided.
Five Prime Therapeutics, Inc.


02/18/16
20160046627 

Itk and jak kinase inhibitors


Salts thereof, their synthesis, and their use as itk and jak3 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and or disorders such disease associated with abnormal cell growth such as autoimmune, inflammation, rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis, ulcerative colitis, psoriatic arthritis, psoriasis, crohn's, metabolic and cancer diseases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions and processes for preparing the compounds of the invention..

02/18/16
20160046612 

Heterocyclic derivative and pharmaceutical drug


Wherein r1 and r2 are the same or different aromatic rings, etc., and ring a is a heterocyclic ring. The compound of the invention or a pharmaceutically acceptable salt thereof has potent mpges-1 inhibiting activity and is useful as an agent for the treatment or prevention of a disease, such as rheumatoid arthritis, osteoarthritis, temporomandibular joint disorders, low back pain, endometriosis, dysmenorrhea, overactive bladder, malignant tumors or neurodegenerative disease..

02/18/16
20160045520 

Use in one pill tablet capsule minocycline acycloguanosine atorvastatin and vitamin d3 in the treatment of rheumatoid arthritis


The present invention has for object the use of minocycline or its equivalent forms, or any form of tetracycline in combination with acycloguanosine or any equivalent form (antiviral), atorvastatin or any equivalent form (lipophilic statins) and vitamin d3 (pro hormone) for the preparation of a single compound addressed to treatment of autoimmune type of rheumatoid arthritis in the three stages of development, whether it is active or quiescent phase or forms of diseases eziopatologicamente equivalent, but some degenerative. The efficacy of this combination has been proven by many studies on individual components.

02/18/16
20160045516 

Treatment methods using pharmaceutical solid state forms


The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include form i anhydrate and form iv and form v solvates.
Harbor Therapeutics, Inc.


02/18/16
20160045475 

Methods for the treatment of diseases ameliorated by pde4 inhibition using dosage titration of apremilast


Methods of treating, managing or preventing diseases ameliorated by inhibiting pde4 such as psoriasis, ankylosing spondylitis, behcet's disease, rheumatoid arthritis, atopic dermatitis, crohn's disease, and ulcerative colitis are disclosed. Specific methods encompass the administration of apremilast in specific dosage titration schedule, alone or in combination with a second active agent..
Celgene Corporation


02/11/16
20160039928 

Anti-il-17a antibodies and their use in treating autoimmune and inflammatory


The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine il-17 a. The disclosure more specifically relates to specific antibodies and proteins that are il-17 a antagonists (inhibit the activities of il-17 a and il-17 af) and are capable of inhibiting il-17 a induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo.
Novartis Ag


02/11/16
20160039807 

Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)


Wherein cy, l1, g, and r1 are as described herein. The present invention relates to novel compounds according to formula (i) that antagonize gpr84, a g-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (ibd), rheumatoid arthritis, vasculitis), lung diseases (e.g.

02/04/16
20160032001 

Anti-rankl antibodies and methods of use


The present invention provides anti-rankl monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.. .
Apexigen, Inc.


01/28/16
20160024580 

Polymorphism of thrombospondin-1 as a biomarker for susceptabiltiy to dry eye


Embodiments of the invention relate to single nucleotide polymorphisms (snps) in thrombospondin 1 gene (thb-s1) that are herein linked to an increased risk for dry eye (also known as keratoconjunctivitis). The polymorphisms disclosed herein are directly useful for the diagnosis of an increased risk for dry eye, as well as for the determination of patient treatment pre- and post-surgery (e.g.
Trustees Of Boston University


01/28/16
20160024220 

Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis


The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-cd6 monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular


01/28/16
20160024082 

P2x7 modulators


The present invention is directed to a compound of formula (i) or (ia) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) or (ia) and methods comprising administering of compounds of formula (i) or (ia) for treating rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv


01/28/16
20160024074 

Process for extracting the alkaloid fraction of rhodophiala bifida (herb.) traub and uses thereof


The present invention describes a method for completely extracting the alkaloid fraction (montanine) of rhodophiala bifida (herb.) traub from bulbs of rhodophiala bifida. The present invention further describes a method for treating inflammation using pharmaceutical compositions containing the alkaloid fraction of rhodophiala bifida as the active ingredient.
Hospital De ClÍnicas De Porto Alegre (hcpa)


01/28/16
20160022692 

Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors


Provided herein are methods, kits, and pharmaceutical compositions that include a pi3 kinase inhibitor for treating rheumatoid arthritis or asthma.. .
Infinity Pharmaceuticals, Inc.


01/21/16
20160018407 

Metabolic profiles


The invention relates to the use of endogenous metabolites to produce a metabolic profile of a disorder or disease in a subject, e.g. An autoimmune disease, in particular rheumatoid arthritis, and the analysis of such metabolic profiles in order to find disturbances in such profiles in a subject which are caused by or correlated with the said diseases or disorders.
Anamar Ab


01/21/16
20160016962 

P2x7 modulators


The present invention is directed to a compound of formula (i) formula (i) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) and methods comprising administering to a subject at least one compound selected from compounds of formula (i) for treating diseases mediated by p2x7 receptor activity, such as rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv


01/21/16
20160015685 

Furo [3, 2-b] pyrr0l-3-0nes as cathespin s inhibitors


Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.. .

01/14/16
20160010089 

Organic compositions to treat epasi-related diseases


The present disclosure relates to methods of treating epas1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a rnai agent to epas1.. .
Arrowhead Research Corporation


01/14/16
20160009716 

2 - (azaindol-2-yl) benz imidazoles as pad4 inhibitors


Compounds of formula (i) wherein; r1 is hydrogen or c1-6alkyl; r2 is hydrogen, c1-6alkyl, perhalomethylc0-5alkyl-o—, or c1-6alkoxy; r3 is hydrogen, c1-6alkyl, or c1-6alkoxyc1-6alkyl; r4 is hydrogen, c1-6alkyl, perhalomethylc1-6alkyl; or unsubstituted c3-6cycloalkylc1-6alkyl; a is c—r5 or n; b is c—r6 or n; d is c—r7 or n; with the proviso that at least one of a, b, and d, is n; r5 is hydrogen or c1-6alkyl; r6 is hydrogen or c1-6alkyl; r7 is hydrogen, c1-6alkyl, c1-6alkoxy, or hydroxy; r8 is hydrogen or c1-6alkyl, with the proviso that one of r4 and r8 is hydrogen; r9 is hydrogen or hydroxy; rio is hydrogen or c1-6alkyl; and salts thereof are pad4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.. .
Glaxo Group Limited


01/07/16
20160002354 

Antibodies to bone marrow stromal antigen 1


The invention provides antibodies which bind to the adp-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided.
Oxford Biotherapeutics Ltd


01/07/16
20160002328 

Methods of treating kawasaki disease using il-1beta antibodies


This invention relates to a novel use of il-1β-ligand/il-1 receptor disrupting compounds (herein referred to as “il-1beta compounds”); such as small molecular compounds disrupting il-1b ligand-il-1 receptor interaction, il-1b antibodies or il-1 receptor antibodies, e.g. Il-1b binding molecules described herein, e.g.
Novartis Ag


01/07/16
20160002326 

Compositions and methods for treating rheumatoid arthritis


The treatment of rheumatoid arthritis using engineered multivalent and multispecific binding proteins that target tnf and il-17 is provided.. .
Abbvie Inc.


01/07/16
20160002295 

Methods and compositions for the treatment of bone remodeling disorders


The present invention relates to methods and compositions for treating disease related to disorders of bone remodeling. In particular, the present invention relates to compositions and methods for treating rheumatoid arthritis..
Yissun Research Development Company Of The Hebrew University Of Jerusalem, Ltd


01/07/16
20160002243 

Inhibitors of bruton's tyrosine kinase


This application discloses compounds according to generic formula (i) wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.
Hoffmann-la Roche Inc.


01/07/16
20160002206 

Inhibitors of bruton's tyrosine kinase


This application discloses compounds according to generic formula i: (i) wherein all variables are defined as described herein, which inhibit btk. The compounds disclosed herein are useful to modulate the activity of btk and treat diseases associated with excessive btk activity.
Hoffmann-la Roche Inc.


01/07/16
20160000849 

Composition for remedying or treating rheumatoid arthritis and osteoarthritis


The present invention relates to the composition according to the present invention, which has not only the effect of suppressing inflammation and pain, which are the common symptoms of acute and chronic arthritis, but also the effect of alleviating movement disorders, which are the symptoms of chronic arthritis.. .
Hanpoong Pharm & Foods Co., Ltd.


01/07/16
20160000844 

A composition for improving joint health, or for preventing and treating rheumatoid arthritis and osteoarthritis


The present invention relates to a composition for helping with joint health or preventing, alleviating or treating rheumatoid arthritis and osteoarthritis, which is based on the results of tests conducted using an inflammatory cell model, an osteoarthritis animal model and an acute arthritis animal model.. .
Hanpoong Pharm & Foods Co., Ltd.


12/31/15
20150377907 

Diagnosis of rheumatoid arthritis


The present invention provides a method of diagnosing rheumatoid arthritis (ra), comprising: testing a sample from a subject for the presence or absence of antibodies against oxidised collagen ii; wherein the presence of antibodies against oxidised collagen ii in the sample is indicative of ra in the subject. The present invention also provides a method for identifying whether a subject responds to a disease modifying anti-rheumatic drug (dmard) and related methods of treating ra, a method for identifying whether a subject responds to an anti-tnf biologic and related methods of treating ra, and a method of diagnosing osteoarthritis (oa)..
King's Colege London




Rheumatoid Arthritis topics: Rheumatoid Arthritis, Osteoarthritis, Autoimmune, Multiple Sclerosis, Immune Disease, Autoimmune Disease, Antibodies, Astaxanthin, Hyaluronate, Hyaluronic Acid, Joint Pain, Hyaluronan, Immune Diseases, Autoimmune Diseases, Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Rheumatoid Arthritis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Rheumatoid Arthritis with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.8829

5664

2 - 1 - 101